| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| IN8bio Inc. | INB-400 | Glioblastoma Multiforme(GBM) | Phase 2 | Enrollment Initiation | intracerebral | Oncology |
| IN8bio Inc. | INB-100 | Acute myeloid leukemia (AML) | Phase 2 | Data Released | Intravenous | Oncology |
| Incannex Healthcare Inc. | IHL-675A | Rheumatoid arthritis, inflammatory bowel disease and lung inflammation | Phase 2 | Enrollment Initiation | oral | Immunology: Anti-TNF |
| Incannex Healthcare Inc. | PSX-001 (Psilocybin treatment) - (PsiGAD2) | Generalized anxiety disorder (GAD) | Phase 2 | Ongoing | Oral | Psychiatric |
| Incannex Healthcare Inc. | IHL-42X - (RePOSA) | Obstructive sleep apnea (OSA) | Phase 2/3 | Data Released | Oral | Respiratory |
| Incyte Corporation | Parsaclisib | Follicular lymphoma | NDA Filing | Withdrawn | Oral | Oncology |
| Incyte Corporation | Parsaclisib | Marginal Zone Lymphoma | NDA Filing | Withdrawn | Oral | Oncology |
| Incyte Corporation | Elraglusib Plus Retifanlimab | 1L Advanced pancreatic cancer | Phase 2 | Trial Planned | Intravenous | Oncology |